Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Supplementing With IL-2 to Verifiably eRadicate Radiological Progression

NCT07063875 is registered in ClinicalTrials.gov with St Vincent's Hospital, Sydney as lead sponsor.

NCT NCT07063875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07063875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Supplementing With IL-2 to Verifiably eRadicate Radiological Progression
Lead sponsor
St Vincent's Hospital, Sydney
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2025
Completion date
September 30, 2027
Enrollment
8 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic uveal melanoma, metastatic uveal melanoma in the liver, uveal melanoma